Focus on Safety:
New Alternative for Breast and Facial Reconstruction
 LifeNet Health's internationally recognized Skin and Wound Allograft Institute (SWAI) announces a new decellularized, regenerative human matrix processed with a patented technology that safely renders the allograft tissue acellular without compromising its biomedical properties.
Julie Gustafson, CWCMS, is product manager for LifeNet Health's Bio-Implants Division. She says new DERMACELL® Advanced Decellularized Dermis uses SWAI's pioneering Matracell® technology to create safe and effective acellular bio-implant solutions for today's leading surgeons.
"Matracell® is a patented and validated process that removes donor cells and greater than 97% of donor genetic material," says Gustafson. The result is an acellular tissue which maintains its desired biomechanical and biochemical properties for its intended surgical application.
Gustafson points to the advantages of the product's intact acellular framework. "With Dermacell, the collagen, elastin and native growth factors which have been associated with healing are retained, making it ideal for use in reconstructive surgery, including breast and facial reconstruction." Other product benefits include pull-out strength asnd load to failure which are comparable to existing allograft products.
As for safety and ease of handling, Dermacell has a 10-6 SAL (Sterility Assurance Level) and can be stored in a fully hydrated state at room temperature of 15°-30° C. SWAI's patented Preservon® process acts as a humicant to maintain the moisture within the allograft while providing a bacteriostatic environment. A 30-second rinse prior to implantation is the only preparation required—a significant advantage over conventional freeze-dried allograft alternatives.
"Dermacell Advanced Decellularized Dermis is the only allograft product of its kind on the market today," says Bud Brame, Vice President of Tissue Service for LifeNet Health. "It's another solution made possible through research, technology and LifeNet Health's ongoing commitment to leadership in the field of regenerative medicine."
|
